Subgroup-specific structural variation across 1,000 medulloblastoma genomes.

Developmental & Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Ontario M5G 1L7, Canada.
Nature (Impact Factor: 42.35). 07/2012; 488(7409):49-56. DOI: 10.1038/nature11327
Source: PubMed

ABSTRACT Medulloblastoma, the most common malignant paediatric brain tumour, is currently treated with nonspecific cytotoxic therapies including surgery, whole-brain radiation, and aggressive chemotherapy. As medulloblastoma exhibits marked intertumoural heterogeneity, with at least four distinct molecular variants, previous attempts to identify targets for therapy have been underpowered because of small samples sizes. Here we report somatic copy number aberrations (SCNAs) in 1,087 unique medulloblastomas. SCNAs are common in medulloblastoma, and are predominantly subgroup-enriched. The most common region of focal copy number gain is a tandem duplication of SNCAIP, a gene associated with Parkinson's disease, which is exquisitely restricted to Group 4α. Recurrent translocations of PVT1, including PVT1-MYC and PVT1-NDRG1, that arise through chromothripsis are restricted to Group 3. Numerous targetable SCNAs, including recurrent events targeting TGF-β signalling in Group 3, and NF-κB signalling in Group 4, suggest future avenues for rational, targeted therapy.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The Hedgehog (Hh) pathway is an evolutionarily conserved sign-aling axis that directs embryonic patterning through strict tempo-ral and spatial regulation of cell proliferation and differentiation 1 . Developmental aberrations in Hh signaling result in dysmorphology, such as cyclopism, holoprosencephaly and limb deformity, when its output is absent or decreased 2 and in cancer predisposition, as is seen in nevoid basal cell carcinoma syndrome (Gorlin syndrome) 3 , when its output is increased or unchecked 1,4 . In canonical Hh signaling, several morphogens (sonic hedgehog (SHH), Indian hedgehog (IHH) and desert hedgehog (DHH)) 5,6 have been identified that bind to the multipass cell-surface receptor Patched (PTCH1) 1 . When not bound by Hh ligand, PTCH1 inhibits the G protein–coupled receptor, SMO 7 . Once bound by ligand, how-ever, PTCH1 no longer inhibits SMO, allowing SMO to positively regulate mobilization of the otherwise latent zinc finger transcription factor GLI2, residing in the cilia, to the nucleus, where GLI2 transac-tivates the GLI1 promoter 8–10 . GLI1 and GLI2 directly transactivate transcription of Hh target genes, several of which are involved in proliferation, such as MYCN and CCND1 (ref. 11). GLI1 also serves to amplify the output of Hh signaling in a positive feedback loop by activating transcription of GLI2, albeit indirectly 12 . Ultimately, the transcriptional programs mediated by Hh signaling orchestrate an array of events based on cellular, temporal and spatial context, with perhaps the most phenotypically consequential event being an increase in cell proliferation. Inappropriate activation of Hh signaling results in tumor formation in several tissue lineages, including skin, brain, muscle, breast and pancreas 13–15 . The tumors most commonly associated with aberrant Hh signaling are basal cell carcinoma (BCC) and medulloblastoma, given their prevalence in individuals with germline mutations in PTCH1 (Gorlin syndrome) 3,4 . However, the overwhelming major-ity of Hh-driven BCCs and medulloblastomas activate Hh signaling through sporadic somatic mutations in PTCH1 or other components of the Hh pathway 14,16,17 . These include activating mutations in SMO
    Nature Medicine 07/2014; 20(7):732-740. DOI:10.1038/nm.3613 · 28.05 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The present study describes the recent advances in the identification of targetable genomic alterations in pediatric cancers, along with the progress and associated challenges in translating these findings into therapeutic benefit. Each field within pediatric cancer has rapidly and comprehensively begun to define genomic targets in tumors that potentially can improve the clinical outcome of patients, including hematologic malignancies (leukemia and lymphoma), solid malignancies (neuroblastoma, rhabdomyosarcoma, Ewing sarcoma, and osteosarcoma), and brain tumors (gliomas, ependymomas, and medulloblastomas). Although each tumor has specific and sometimes overlapping genomic targets, the translation to the clinic of new targeted trials and precision medicine protocols is still in its infancy. The first clinical tumor profiling studies in pediatric oncology have demonstrated the feasibility and patient enthusiasm for the personalized medicine paradigm, but have yet to demonstrate clinical utility. Complexities influencing implementation include rapidly evolving sequencing technologies, tumor heterogeneity, and lack of access to targeted therapies. The return of incidental findings from the germline also remains a challenge, with evolving policy statements and accepted standards. The translation of genomic discoveries to the clinic in pediatric oncology continues to move forward at a brisk pace. Early adoption of genomics for tumor classification, risk stratification, and initial trials of targeted therapeutic agents has led to powerful results. As our experience grows in the integration of genomic and clinical medicine, the outcome for children with cancer should continue to improve.
    Current Opinion in Pediatrics 12/2014; 27(1). DOI:10.1097/MOP.0000000000000172 · 2.74 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: We undertook a comprehensive clinical and biological investigation of serial medulloblastoma biopsies obtained at diagnosis and relapse. Combined MYC family amplifications and P53 pathway defects commonly emerged at relapse, and all patients in this group died of rapidly progressive disease postrelapse. To study this interaction, we investigated a transgenic model of MYCN-driven medulloblastoma and found spontaneous development of Trp53 inactivating mutations. Abrogation of p53 function in this model produced aggressive tumors that mimicked characteristics of relapsed human tumors with combined P53-MYC dysfunction. Restoration of p53 activity and genetic and therapeutic suppression of MYCN all reduced tumor growth and prolonged survival. Our findings identify P53-MYC interactions at medulloblastoma relapse as biomarkers of clinically aggressive disease that may be targeted therapeutically. Copyright © 2015 The Authors. Published by Elsevier Inc. All rights reserved.
    Cancer Cell 12/2014; 27(1):72-84. DOI:10.1016/j.ccell.2014.11.002 · 23.89 Impact Factor


Available from
Jun 1, 2014